# Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

> **NCT00004088** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 77 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** melphalan
- **DRUG:** pamidronate disodium
- **DRUG:** thalidomide
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00004088
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04-13
- **Primary completion:** 2018-01-09
- **Final completion:** 2018-01-09
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004088, "Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00004088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*